Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,001–1,100 of 2,039
Obesity as a modifiable risk factor in patients with chronic kidney disease
Morales, E., Jenssen, T. G., Bevc, S., Miglinas, M., Martin, W. P., Theodorakopoulou, M. P., Jørgensen, M. B., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf231 · Cited by 10
Wang, Z., Pan, T., Lv, W., Tang, J., Chen, Y., Zhu, X., Zhang, Q., Jing, F., Yin, H., Lu, D., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02459-6 · Cited by 6
Kan, R., Wang, S., Meng, X., Guo, Y., Li, D., & Yu, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01995-z · Cited by 7
Yokote, K., Fukushima, Y., Shingaki, T., Oura, T., & Ogawa, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70315 · Cited by 6
Tirzepatide-Induced Liver Injury: A Rare Complication
Spaeth, L. D., Jordan, K. M., Barlow, M., & Cottrell, D. A. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.11.009 · Cited by 5
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
Hong, A. T., Lin, F., Baxter, S. L., & Weinreb, R. N. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.12.003 · Cited by 8
Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
Pharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes
Hong, A. T., Lin, F., Keenan, J. D., & Stewart, J. M. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.02.002 · Cited by 9
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
“However, given the comparable magnitude of liver-related effects in phase 2 MASH trials and head- to-head studies demonstrating greater reductions in HbA1c 94 and body weight 78 with tirzepatide, it is reasonable to infer similar hepatic benefits, particularly since much of the liver improvement appears to be weight-l…”
Edvardsson, C. E., Zhang, X., Emous, T. A., Adermark, L., Witley, S., Ericson, M., Schmidt, H. D., & Jerlhag, E. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106219 · Cited by 7
Al-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
“12 However, a substantial proportion of weight lost with tirzepatide and similar agents is lean mass, including muscle mass, ranging from 15% to 50% of total weight loss.”
Chen, S.-Y., Telfser, A. J., Olzomer, E. M., Vancuylenberg, C. S., Zhou, M., Beretta, M., Li, C., Alexopoulos, S. J., Turner, N. A., Byrne, F. L., et al. (2024) · Clinical Science · doi:10.1042/cs20231016 · Cited by 9
“…potential future direction is to explore newer GLP-1-RA molecules, such as tirzepatide, which also acts on the glucose-dependent insulinotropic polypeptide (GIP) receptor and has shown stronger weight loss and HbA1c-lowering effects than semaglutide at the doses tested in the SURPASS-2 trial [62].”
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
Ayesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12091943 · Cited by 5
Kędzierska-Kapuza, K., Łopuszyńska, I., Niewiński, G., Franek, E., & Szczuko, M. (2024) · Nutrients · doi:10.3390/nu16183216 · Cited by 5
“%) achieved in obese and diabetic patients [94].”
BackgroundReal-world efficacy of tirzepatide in patients with heart failure without diabetes
Augusto, S. N., Kaelber, D. C., & Tang, W. H. W. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.102998 · Cited by 8
“15 Collectively, these findings support the hypothesis that tirzepatide not only aids in weight loss and diabetes prevention but also provides critical cardiovascular protection, as reflected in the reduced rates of acute HF and MACE.”
Kamrul-Hasan, A. B. M., Pappachan, J. M., Dutta, D., Nagendra, L., Kuchay, M. S., & Kapoor, N. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.101731 · Cited by 8
Chunduri, S., Bidaoui, G., Hussein, M. H., Patel, M., Abdelmaksoud, A., Mohamed, M., Attia, A. S., Tatum, D. M., Borgi, J., & Toraih, E. A. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07757-3 · Cited by 6
Murtaza, S., Sohail, R., Akram, B., Tahira, S., Zaman, M., & Mehmood, S. N. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70196 · Cited by 5
“…a glucose-dependent insulino-tropic peptide GIP, showing indirect benefits in OSA through weight reduction; however, its adverse effects, including gastro-intestinal disturbances and rare but serious complications like pancreatitis and thyroid tumours, limit its use (FDA 2023; Frias et al. 2021).”
Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101626 · Cited by 6
Araki, E., Sakaguchi, M., Fukuda, K., & Kondo, T. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13896 · Cited by 6
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Chai, S., Zhang, R., Carr, R. D., Deacon, C. F., Zheng, Y., Rajpathak, S. N., Chen, J., & Yu, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203187 · Cited by 8
“However, recent clinical trials with tirzepatide, a dual GIP and GLP-1 receptor agonist, have shown that this drug has superior efficacy in terms of the antihyperglycemic effects and weight loss compared to the selective GLP-1 receptor agonist semaglutide (34), thus highlighting the benefit of harnessing the actions o…”
BackgroundManagement of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
Onishi, Y., Oura, T., & Takeuchi, M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01534-5 · Cited by 6
Kaore, S. N., Bhavya, B., Khasbage, S. U., & Atal, S. (2024) · Cureus · doi:10.7759/cureus.56939 · Cited by 12
“Also, Tirzepatide has been included in the recent version of the widely accepted ADA (American Diabetes Association) guidelines for the management of T2DM, wherein it has been considered as having very high glucose lowering and weight loss efficacy [18].”
BackgroundGenetics, pharmacotherapy, and dietary interventions in childhood obesity
Son, J. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12861 · Cited by 15
Parsiani, R., Grace, T., Green, C. R., Castle, J. R., & Wilson, L. M. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_773_24 · Cited by 5
Hansrivijit, P., Ortega-Montiel, J., Wexler, D. J., Patorno, E., & Paik, J. M. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101013 · Cited by 6
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Lawati, A. A., Alhabsi, A. N., Rahul, R., Savino, M.-L., Alwahaibi, H., Das, S., & Lawati, H. A. (2025) · Diseases · doi:10.3390/diseases13050129 · Cited by 5
Metzner, A., Willems, S., Borof, K., Breithardt, G., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Fabritz, L., Geßler, N., Goette, A., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.2374 · Cited by 5
Patoulias, D., Michailidis, T., Papadopoulos, C. E., Karagiannis, A. I., & Doumas, M. N. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.12.001 · Cited by 5
Recent Advances in Anti-Obesity Drugs
Son, J. W. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.113 · Cited by 5
“SURPASS-2는 메트 포민(metformin)으로 혈당조절이 충분하지 않은 2형당뇨 병 환자 1,879명을 대상으로 tirzepatide와 세마글루타이드 를 일대일 비교한 연구이다[58].”
Adipositas und Typ-2-Diabetes (Update 2023)
Clodi, M., Toplak, H., Resl, M., Brix, J. M., Leitner, D. R., Harreiter, J., Hoppichler, F., Wascher, T. C., Schindler, K., & Ludvik, B. H. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02184-6 · Cited by 7
“heit im Vergleich zu Semaglutid gezeigt werden [51].”
BackgroundAn Introduction to Tirzepatide
Bertsch, T. G. (2022) · Clinical Diabetes · doi:10.2337/cd22-0038 · Cited by 5
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.29.454286 · Cited by 5
Koufakis, T., Patoulias, D., Apostolopoulou, M., Georgianos, P. I., & Popovic, D. S. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2559907 · Cited by 5
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Drewa, J., Lazar-Juszczak, K., Adamowicz, J., & Juszczak, K. (2025) · Cancers · doi:10.3390/cancers17091576 · Cited by 7
Short-Term Effects of Tirzepatide in Obese Adults: A Real-World Prospective Study
Adamidis, N., Desalermos, A. P., Papadopoulou, N., Adamidi, S., Koutrakos, T., Kyventidou, M., Georgakopoulou, V., & Adamidis, S. (2025) · Cureus · doi:10.7759/cureus.85970 · Cited by 11
Molecular Afterglow of Lophine‐Based Luminophore and Its Imaging Applications
Yang, J., Yang, Y., Wang, H., Liang, S. H., & Ran, C. (2025) · Angewandte Chemie · doi:10.1002/ange.202507174 · Cited by 5
Oe, Y., Nomoto, H., Cho, K. Y., Omori, T., Nakamura, K., Takahashi, A., Suzuki, Y., Yoshikawa, J., Kato-Sato, A., Furukawa, S., et al. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251378216 · Cited by 4
“18,20 Although the background regimens of subjects were diet and exercise therapy in the SURPASS J-mono trial, the difference in the change in HbA1c was 1.1% (IFCC: 12 mmol/mol) between those receiving 5.0 mg tirzepatide and 0.75 mg dulaglutide, 18 which was similar to our results.”
InfluentialFragozo-Ramos, M. C., Schenker, G., Hepprich, M., Gallo‐Villegas, J., Züger, T., & Garcia‐Tirado, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335060 · Cited by 6
Active Comparator New User Cohort Studies and Matching
Stürmer, T., & Wang, T. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.5792 · Cited by 5
Demidova, T. Y., & Izmaylova, M. Y. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-03 · Cited by 8
A real-world study of tirzepatide for weight loss in adults without diabetes mellitus
Angelopoulos, N., Androulakis, I. P., Rizoulis, A. A., Boniakos, A., Fousteris, E., Mentzelopoulou, V., Petkova, V. B., Paparodis, R. D., Zianni, D., Florakis, D., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01986-0 · Cited by 9
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“…endpoint in patients with type 2 diabetes mellitus (T2DM), especially when compared with placebo ( SURPASS 1 ) [94], semaglutide 1 mg ( SURPASS 2 ) [95], insulin degludec as an add-on to metformin with or without SGLT2 inhibitor ( SURPASS 3 ) [96], insulin glargine ( SURPASS 4 ) [97] and placebo +…”
Self-citationAlper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
“…weight loss, Orforglipron’s lipid and blood-pressure benefits approach the magnitude seen with the dual GIP/GLP-1 receptor agonist tirzepatide [45, 46], suggesting that its non-peptide, G-protein-biased signaling profile may confer disproportionate cardiometabolic effects beyond those…”
Heart failure evidence update 2026
Liori, S., Kapelios, C. J., Savarese, G., & Filippatos, G. S. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10609-3 · Cited by 10
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych, V., Shypilova, I., & Bolgova, O. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1790247 · Cited by 7
“Phase 2b studies demonstrated tirzepatide produces HbA1c reductions of up to 2.4% versus placebo at 26 weeks (Thomas et al., 2021), with Phase 3 SURPASS trials confirming mean HbA1c reductions from baseline of 2.07 percentage points with tirzepatide 15 mg (treatment difference vs. placebo: −2.11 percentage points; SUR…”
InfluentialCorrao, S., Scibetta, S., Mirarchi, L., Amodeo, S., Corrao, G., & Calvo, L. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113243 · Cited by 4
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Tirzepatide: A First-in-class Twincretin for the Management of Type 2 Diabetes
Jaswal, S., Bisht, P., Patel, R., Parveen, D., Gupta, G. D., & Verma, S. K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230130153219 · Cited by 5
Madigan, C. D., King, J. A., Taylor, C., Hoekstra, S. P., Graham, H. E., Kirk, N., Fenton, J. M., & Goosey-Tolfrey, V. L. (2024) · Obesity Reviews · doi:10.1111/obr.13785 · Cited by 6
Tirzepatide increased force of contraction in the isolated human atrium
Neumann, J., Hofmann, B., Kirchhefer, U., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04214-8 · Cited by 4
New Approaches to the Treatment of Severe Obesity—Prehabilitation as the Key to Success
Budny, A., Janczy, A., & Mika, A. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00652-1 · Cited by 4
Agonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
Alonso, S. P., Valdés, S., & Doulatram‐Gamgaram, V. K. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107042 · Cited by 4
Wang, M., Dong, T., Lucero, M., Pan, W., Wang, X., Zhou, L., & Meng, Y. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.06.012 · Cited by 6
A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide
Huang, M., Liu, G., Zhang, C., Wang, Y., Liu, S., & Zhao, J. L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1608657 · Cited by 12
Desai, A., Khataniar, H., Tabaku, F., Hashash, J. G., Farraye, F. A., & Kochhar, G. S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01835-y · Cited by 7
Galindo, R. J., Lee, C. J., Allen, S. E., Dib, A., Boye, K. S., Thieu, V. T., Dong, W., Sapin, H., & Wiese, R. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16620 · Cited by 3
Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?
Argyrakopoulou, G., Gitsi, E., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00654-8 · Cited by 4
“However, its use in T1DM remains off-label, with limited studies exploring its impact on this population [32].”
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
Garbaccio, N. C., Smith, J. E., Posso, A. N., Schonebaum, D. I., Foster, L., Cordero, J. J., Foppiani, J. A., Alvarez, A. H., Choudry, U. H., & Lin, S. J. (2025) · Aesthetic Plastic Surgery · doi:10.1007/s00266-025-05112-3 · Cited by 9
“Two studies did not reach WLP within the study period and were excluded from this analysis [22, 25].”
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
Kahles, F., Rau, M., Reugels, M., Foldenauer, A. C., Mertens, R. W., Arrivas, M. C., Schröder, J. H., Idel, P., Moellmann, J., van der Vorst, E. P. C., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01454-3 · Cited by 5
“Recent efforts have led to the development of combined GLP-1/GIP receptor co-agonists which in clinical trials were importantly found to have more potent blood glucose lowering and body weight reducing effects than sole GLP-1 receptor agonists [18].”
BackgroundLiuzzo, G., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac384 · Cited by 4
Evidências cientificas sobre o uso de tirzepatida como tratamento da obesidade
Guimarães, B. C. D. S., Zanoteli, H. C., Chaves, R. P., Marcos, C. R. S. A., Aquino, M. E. F. V. D., Rosseto, J. S., Lopes, R. L., Lampert, A. R., & Peroba, G. G. P. D. A. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n4-137 · Cited by 15
Combining Metabolic Surgery with Medications for Type 2 Diabetes: Is There a Benefit?
Sudlow, A. C., Pournaras, D. J., & le Roux, C. W. (2022) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_16_22 · Cited by 4
Taylor, S. I., Montasser, M. E., Yuen, A. H., Fan, H., Yazdi, Z. S., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Muniyappa, R., Streeten, E. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15143 · Cited by 6
“To test these hypotheses, we recruited individuals who are homozygous for two relatively common missense variants: rs1801483 (p.G40S) in GCGR and rs1800437 (p.E354Q) in GIPR.”
BackgroundInfluentialReitzel, S. B., Bøgelund, M., Basse, A., Barszczewska, O., & Ren, H. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2231275 · Cited by 9
De, R., Prasad, F., Stogios, N., Burin, L. M., Ebdrup, B. H., Knop, F. K., Hahn, M., & Agarwal, S. M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2254698 · Cited by 8
Matza, L. S., Stewart, K. D., Redig, J., Howell, T. A., Morris, W., Newson, R. S., Yasui, A., Ishak, J., & Boye, K. S. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2316400 · Cited by 4
Shao, Y., Chen, Y., Zhu, M., Liu, Y., Chen, F., Wang, M., Sun, P. G., Fu, W., Huang, J., Sheng, S., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s457830 · Cited by 4
“19 Besides, the SURMOUNT-4 trial demonstrated that the overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.”
BackgroundInfluentialThe effect of incretin-based drugs on the riks of acute pancreatitis: a review
Czaplicka, A., & Kaleta, B. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01430-6 · Cited by 4
Hösli, P., Renström, F., Laimer, M. W., Cavelti‐Weder, C., Gastaldi, G., Lehmann, R., & Brändle, M. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004108 · Cited by 4
Kosaraju, S., & Zhang, R. M. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s473319 · Cited by 7
“7 A pooled analysis of SURPASS trials further showed that tirzepatide increased the odds of achieving normoglycemia by 16 times compared to control.”
MethodRecent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Finks, S. W., Benavides, D., Martin, A. G., & Carmon, A. S. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2071 · Cited by 5
“4,11,14 However, in-depth pharmacist involvement (i.e., weekly visits with advice for specific safety concerns, shared decision-making, de-escalation of dose, etc.) influencing discontinuation rates and improved outcomes should not be overlooked.”
Wang, S., Schwartz, P. F., & Mancuso, J. P. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02494-5 · Cited by 5
Slattery, J. D., Rambousek, J. R., Tsui, E. W., Honeycutt, M. K., Goldberg, M., Graham, J. L., Wietecha, T., Wolden‐Hanson, T., Williams, A. L., O’Brien, K. D., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1503096 · Cited by 5
“Although the FDA recently approved the use of the long-acting and highly effective GLP-1R agonist, semaglutide (3), it can also be associated with mild to moderate gastrointestinal (GI) side effects (3, 4), underscoring the need for continued optimization of existing treatments.”
Rajab, A. M., Pearson, S. M., & Ajjan, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16332 · Cited by 7
Odoardo, L. A. F. D., Zucchetti, O., Sciatti, E., D’Isa, S., D’Elia, E., & Senni, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf032 · Cited by 6
Hassan, M. G., Hassan, D., & Hassan, G. A. (2025) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2025.05.007 · Cited by 5
Park, B. G., Kim, G. M., Lee, H., Ryu, J. H., Kim, D., Seong, J. Y., Kim, S., Park, Z., Kim, Y., Lee, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14546 · Cited by 4
Surpassing insulin glargine in type 2 diabetes with tirzepatide
Khoo, B. C. E., & Tan, T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02279-0 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Macronutrient composition and metabolic regulation: Do our islets care what we eat?
Pesta, D. H., & Jordan, J. (2022) · Acta Physiologica · doi:10.1111/apha.13895 · Cited by 4
Updates of incretin‐related drugs for the treatment of type 2 diabetes
Araki, H., Matsumura, T., Furukawa, N., & Araki, E. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13945 · Cited by 4
Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not?
Patoulias, D., Dimosiari, A., & Fragakis, N. (2023) · Future Cardiology · doi:10.2217/fca-2022-0112 · Cited by 4
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0105 · Cited by 6
“In allen drei Dosierungen (5, 10, 15 mg) war Tirzepatid hinsichtlich der glukosesenkenden und gewichts-reduzierenden Wirkung Semaglutid überlegen [23].”
Giorgino, F., Franco, D. R., Nicolay, C., Hemmingway, A., Rodríguez, Á., & Wiese, R. J. (2024) · Diabetes Care · doi:10.2337/dc23-2366 · Cited by 7
Aung, N. L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0038 · Cited by 5
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.